About Gradalis
Gradalis is a Healthcare company based in Carrollton (United States) founded in 2010. Personalized autologous vaccines for advanced cancer are developed. It operates on a HealthTech model. Gradalis has raised $80.66 million across 4 funding rounds from investors including state.tx.us. Gradalis offers products and services including Vigil. Its focus areas include Biotechnology and Cancer Immunotherapy. Its legal entity is Gradalis, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Gradalis is engaged in advancing cancer treatment through personalized immunotherapy with its Vigil platform. The company is dedicated to empowering patients immune systems to identify and destroy cancer cells. Vigil is applied in treating ovarian cancer and explored for other solid tumor types. Solutions are developed for use alone or in combination with other treatments. The expertise and innovation are driven by a committed team in the healthcare sector.
- Total Equity Funding$80.66M (USD)
in 4 rounds
- Latest Funding Round$12.73M (USD), Series C
Jun 2025
- Investors
Products & Services of Gradalis
Gradalis offers a comprehensive portfolio of products and services, including Vigil.
Vigil is developed as personalized cancer immunotherapy treatment.
Apps and channels of Gradalis
its YouTube channel Gradalis Marketing has 0026 subscribers.
Funding Insights of Gradalis
Gradalis has successfully raised a total of $80.66M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $12.73 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80.66M
- Total Rounds 4
- Last Round Series C — $12.73M
- First Round $24M
(Jan 2013)
- Investors Count 1
All 4 funding rounds of Gradalis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $12.73M | Series C | – | – | – |
| Nov 2023 | $9.9M | Grant | – | – | |
| Mar 2018 | $43.94M | Series C | – | – | – |
| Jan 2013 | $24M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in Gradalis
Gradalis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include state.tx.us.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| state.tx.us |
Investor details for Gradalis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gradalis
18 people are tracked at Gradalis (7 in leadership, 7 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Rebecca Lutz | Director Of Quality Assurance | Leadership |
Staci Horvath | VP Of Site Research | Leadership |
Eric Hall | CFO | Leadership |
Adam Walter | VP, Medical & Scientific Affairs | Leadership |
Ernest Bognar | Chief Operating Officer | Leadership |
Laura Stanbery Nejedlik, Ph.D. | Director Scientific Affairs | Leadership |
Fabienne Kerneis-Stewart | Director Of Manufacturing | Leadership |
Robert Landin | Director | Board & advisors |
David Shanahan | Director | Board & advisors |
Scott Seaman | Director | Board & advisors |
John Nemunaitis | Director | Board & advisors |
Harry Jacobson | Director | Board & advisors |
JF Berry | Director | Board & advisors |
Joseph Cunningham | Director | Board & advisors |
Gladice Wallraven | SVP, Clinical & Regulatory Operations | Team |
Mark Early | General Counsel | Team |
Silvia Jasso Torres | Senior Accountant | Team |
Kay Easterwood-Sanchez | Data Manager | Team |
Complete people profiles for Gradalis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Gradalis
3 dated milestones of Gradalis across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Gradalis is founded.
- Funding First funding round of $24.0M.
- Funding Latest funding round, Series C, of $12.7M.
Competitors of Gradalis
Gradalis has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Gradalis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Gradalis
Websites that share an audience with Gradalis (gradalisinc.com).
Websites whose visitors overlap most with Gradalis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| synergybioscience.com | 100% | 1.4K | #9,904,970 | View details | |
| medtherapybiotech.com | 81% | 5.9K | #2,698,476 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Gradalis (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gradalis
Complete news archive for Gradalis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gradalis
Gradalis was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Gradalis is headquartered in Carrollton, United States. It is registered at Carrollton, Texas, United States.
Gradalis is a funded company, having raised a total of $80.66M across 4 funding rounds to date. The company's 1st funding round was a Series B of $24M, raised on Jan 2013.
Gradalis is engaged in advancing cancer treatment through personalized immunotherapy with its Vigil platform. The company is dedicated to empowering patients immune systems to identify and destroy cancer cells. Vigil is applied in treating ovarian cancer and explored for other solid tumor types. Solutions are developed for use alone or in combination with other treatments. The expertise and innovation are driven by a committed team in the healthcare sector.
Gradalis offers Vigil.
Gradalis has 1 investor. Key investors include state.tx.us.
Gradalis operates through Gradalis, Inc..